Is idelalisib a BTKi?
Novel agents, including Bruton’s tyrosine kinase inhibitors (BTKi; ibrutinib, acalabrutinib), venetoclax, and phosphatidylinositol 3-kinase inhibitors (PI3Ki; idelalisib, duvelisib), have fundamentally changed the chronic lymphocytic leukemia (CLL) treatment landscape, allowing for a chemotherapy-free paradigm for many …
Is idelalisib FDA approved?
On July 23, 2014, the FDA granted accelerated approval to idelalisib (Zydelig tablets; Gilead Sciences, Inc.) for the treatment of patients with relapsed follicular B-cell non-Hodgkin lymphoma or relapsed small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies.
Is idelalisib a tyrosine kinase inhibitor?
Idelalisib is an orally bioavailable ATP-competitive kinase inhibitor that targets the phosphoinositide 3-kinase p110 isoform δ (PI3Kδ) with high potency and selectivity.
What is Zydelig used for?
This medication is used to treat certain types of cancer (such as chronic lymphocytic leukemia-CLL, follicular B-cell non-Hodgkin’s lymphoma, small lymphocytic lymphoma-SLL). Idelalisib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.
What is the difference between ibrutinib and zanubrutinib?
“In this interim analysis, zanubrutinib, compared with ibrutinib, was shown to have a superior response rate, improved progression-free survival, and a lower rate of atrial fibrillation or flutter,” said Peter Hillmen, MBChB, PhD, Professor of Experimental Hematology at the University of Leeds in the United Kingdom.
Who developed Idelalisib?
Idelalisib is a PI3Kδ-specific inhibitor, originally developed by Calistoga as CAL-101 but later acquired by Gilead.
Who makes Copiktra?
Secura picks up an exclusive worldwide license for R&D, commercialization and manufacture of Copiktra in all oncology indications.
Is Idelalisib a chemotherapy?
Idelalisib is the generic name for the trade chemotherapy drug Zydelig®. In some cases, health care professionals may use the trade name Zydelig® when referring to the generic drug idelalisib. Drug type: Idelalisib is a targeted therapy.
Who makes Ibrutinib?
IMBRUVICA® is a once-daily, first-in-class Bruton’s tyrosine kinase (BTK) inhibitor that is administered orally, and is jointly developed and commercialized by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company.
Is idelalisib a chemotherapy?
What kind of drug is idelalisib?
Idelalisib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply.